Bae Moonsuk, Lee Sang Oh, Jo Kyung Wook, Choi Sehoon, Lee Jina, Chae Eun Jin, Do Kyung Hyun, Choi Dae Kee, Choi In Cheol, Hong Sang Bum, Shim Tae Sun, Kim Hyeong Ryul, Kim Dong Kwan, Park Seung Il
Department of Infectious Diseases, University of Ulsan College of Medicine, Seoul, Korea.
Department of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Seoul, Korea.
Infect Chemother. 2020 Dec;52(4):600-610. doi: 10.3947/ic.2020.52.4.600. Epub 2020 Nov 3.
The timeline of infections after lung transplantation has been changed with the introduction of new immunosuppressants and prophylaxis strategies. The study aimed to investigate the epidemiological characteristics of infectious diseases after lung transplantation in the current era.
All patients who underwent lung or heart-lung transplantation at our institution between October 29, 2008 and April 3, 2019 were enrolled. We retrospectively reviewed the patients' medical records till April 2, 2020.
In total, 100 consecutive lung transplant recipients were enrolled. The median follow-up period was 28 months after lung transplantation. A total of 127 post-lung transplantation bacterial infections occurred. Catheter-related bloodstream infection (25/84, 29.8%) was the most common within 6 months and pneumonia (23/43, 53.5%) was the most common after 6 months. Most episodes (35/40, 87.5%) of respiratory viral infections occurred after 6 months, mainly as upper respiratory infections. The remaining episodes (5/40, 12.5%) mostly manifested as lower respiratory tract infections. Seventy cytomegalovirus infections observed in 43 patients were divided into 23 episodes occurring before and 47 episodes occurring after discontinuing prophylaxis. Of 10 episodes of cytomegalovirus disease, four occurred during prophylaxis and six occurred after prophylaxis. Of 23 episodes of post-lung transplantation fungal infection, 7 were aspergillosis and all occurred after the discontinuation of prophylaxis.
Lung transplant recipients experienced a high burden of infection even after 6 months, especially after the end of the prophylaxis period. Therefore, these patients should be continued to be monitored long-term for infectious disease.
随着新型免疫抑制剂和预防策略的引入,肺移植后感染的时间线发生了变化。本研究旨在调查当前时代肺移植后传染病的流行病学特征。
纳入2008年10月29日至2019年4月3日在我院接受肺或心肺移植的所有患者。我们回顾性查阅了患者截至2020年4月2日的病历。
共纳入100例连续的肺移植受者。肺移植后的中位随访期为28个月。共发生127例肺移植后细菌感染。导管相关血流感染(25/84,29.8%)在6个月内最为常见,肺炎(23/43,53.5%)在6个月后最为常见。大多数呼吸道病毒感染发作(35/40,87.5%)发生在6个月后,主要为上呼吸道感染。其余发作(5/40,12.5%)大多表现为下呼吸道感染。在43例患者中观察到70例巨细胞病毒感染,分为预防性用药前发生的23例发作和预防性用药停药后发生的47例发作。在10例巨细胞病毒病发作中,4例发生在预防性用药期间,6例发生在预防性用药后。在23例肺移植后真菌感染发作中,7例为曲霉病,均发生在预防性用药停药后。
肺移植受者即使在6个月后,尤其是在预防期结束后,仍面临较高的感染负担。因此,应对这些患者进行长期的传染病监测。